Zura Bio Highlights TibuSURE Phase 2 Trial Design

Zura Bio ( (ZURA) ) has provided an announcement.

On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation at the 9th Systemic Sclerosis World Congress in Athens, Greece, running March 5–7, 2026. The poster will detail the rationale and structure of the randomized, double-blind, placebo-controlled study but will not include clinical efficacy or safety data.

TibuSURE is the first clinical trial to test dual inhibition of IL-17A and BAFF in diffuse cutaneous systemic sclerosis, using tibulizumab, a bispecific antibody designed to target complementary inflammatory and fibrotic pathways in this rare, progressive autoimmune disease with limited treatment options. The study plans to enroll about 80 adults, dosing every four weeks over 24 weeks with an open-label extension and a primary endpoint based on skin score improvement, with topline results expected in the first half of 2027, underscoring Zura’s strategy to establish a differentiated position in systemic sclerosis and broader autoimmune markets.

The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Spark’s Take on ZURA Stock

According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.

Score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum and positive corporate updates supporting clinical progress and a stated funding runway through 2027. Valuation signals remain constrained by unprofitability and lack of dividend data.

To see Spark’s full report on ZURA stock, click here.

More about Zura Bio

Zura Bio Limited is a clinical-stage biotechnology company focused on immunology, developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with significant unmet need. Its pipeline is led by tibulizumab (ZB-106), in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis, alongside additional candidates crebankitug (ZB-168) and torudokimab (ZB-880) that have completed Phase 1/1b studies.

Average Trading Volume: 682,567

Technical Sentiment Signal: Buy

Current Market Cap: $559.6M

Find detailed analytics on ZURA stock on TipRanks’ Stock Analysis page.